{"denoms":[{"counts":[{"groupId":"BG000","value":"103"}],"units":"Participants"}],"groups":[{"description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"BG000","title":"LY2523355"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.30","value":"62.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"70"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"101"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"93"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"103"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Colorectal Cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Gastroesophageal Cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"title":"Non-Small Cell Lung Cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"Prostate Cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Squamous Cell Carcinoma of the Head and Neck"}],"paramType":"NUMBER","title":"Tumor Type","unitOfMeasure":"participants"}],"populationDescription":"All enrolled participants."}